Journal article
Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
Abstract
A cost-utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (n = 130) versus 4-weekly (once every 4 weeks) (n = 133) BTA dosing for metastatic breast and castration-resistant prostate (CRPC) cancer. Using a decision tree model, we calculated treatment and symptomatic skeletal event (SSE) costs as well as quality-adjusted life-years …
Authors
Tu MM; Clemons M; Stober C; Jeong A; Vandermeer L; Mates M; Blanchette P; Joy AA; Aseyev O; Pond G
Journal
Current Oncology, Vol. 28, No. 3, pp. 1847–1856
Publisher
MDPI
DOI
10.3390/curroncol28030171
ISSN
1198-0052